Cello develops biomimetic cell membrane-coated nanoparticles for targeted delivery of chemotherapy and immunotherapy agents in cancer treatment. Their technology enhances drug efficacy and patient survival rates by utilizing natural cellular properties to improve the stealth and effectiveness of cancer therapies.
Funding
$7.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often lack specificity, leading to systemic toxicity and reduced efficacy. Traditional chemotherapy and immunotherapy agents struggle to selectively target cancer cells, resulting in damage to healthy tissues and compromised patient outcomes. Effective drug delivery methods are needed to improve the therapeutic index of existing cancer therapies.
Solution
Cello develops cell membrane-coated nanoparticles (CNPs) designed for targeted delivery of cancer therapeutics. By cloaking nanoparticles with natural cell membranes, Cello's technology enhances drug delivery to tumors while minimizing off-target effects. These biomimetic CNPs improve the stealth properties of encapsulated drugs, allowing them to evade immune detection and accumulate selectively within the tumor microenvironment. The CNPs can be loaded with chemotherapy agents, immunotherapy agents, or mRNA, offering a versatile platform for various cancer treatment modalities. Preclinical studies have demonstrated significantly improved survival rates and long-term immunity in animal models.
Target Audience
Cello's primary customers are pharmaceutical companies and clinical researchers focused on developing and improving cancer therapies.
Features
- Biomimetic nanoparticles coated with natural cell membranes for enhanced biocompatibility and reduced immunogenicity
- Targeted drug delivery to tumors, minimizing off-target toxicity and improving therapeutic efficacy
- Versatile platform compatible with chemotherapy agents, immunotherapy agents, and mRNA
- Enhanced stealth properties that allow nanoparticles to evade immune detection and prolong circulation time
- Improved drug accumulation within the tumor microenvironment for increased therapeutic effect